Education
About Us
Working with TipRanks
Follow Us
Avisa Diagnostics (FOGCF)
OTHER OTC:FOGCF
FOGCF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.03 - $0.03
Previous CloseN/A
Volume20.00
Average Volume (3M)0.00
Market Cap
$1.92M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.07
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,241,310
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
FOGCF FAQ
What was Avisa Diagnostics’s price range in the past 12 months?
Avisa Diagnostics lowest stock price was $0.03 and its highest was $0.03 in the past 12 months.
What is Avisa Diagnostics’s market cap?
Avisa Diagnostics’s market cap is $1.92M.
When is Avisa Diagnostics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Avisa Diagnostics’s earnings last quarter?
Currently, no data Available
Is Avisa Diagnostics overvalued?
According to Wall Street analysts Avisa Diagnostics’s price is currently Overvalued.
Does Avisa Diagnostics pay dividends?
Avisa Diagnostics does not currently pay dividends.
What is Avisa Diagnostics’s EPS estimate?
Avisa Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avisa Diagnostics have?
Avisa Diagnostics has 43,241,310 shares outstanding.
What happened to Avisa Diagnostics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avisa Diagnostics?
Currently, no hedge funds are holding shares in FOGCF
---
Company Description
Avisa Diagnostics
Avisa Diagnostics Inc. operates a clinical-stage medical device company. It is developing the Avisa BreathTest, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The company offers clinical proof-of-concept through trials in cystic fibrosis, tuberculosis, and communityacquired pneumonia. It focuses on pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia. Avisa Diagnostics Inc. is based in Santa Fe, New Mexico.
---
Technical Analysis
AXIM Biotechnologies
―
Advaxis
―
BioNano Genomics
―
Guided Therapeutics
―
Inmune Bio
―
Idexx Laboratories
―
---